A Fresh Look At AptarGroup (ATR) Valuation After Recent Share Price Weakness

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

AptarGroup (ATR) has been drawing attention after recent share price moves, with the stock up about 5.1% over the past 3 months but showing a 9.5% decline over the past month.

See our latest analysis for AptarGroup.

At the current share price of $129.05, AptarGroup’s recent 1 month share price return of a 9.5% decline contrasts with a 3 month gain of 5.1% and a 3 year total shareholder return of 18.85%. This suggests that momentum has faded after earlier strength.

If you are comparing AptarGroup with other possibilities in the market, it can help to see how it stacks up next to companies highlighted in our 20 top founder-led companies

With AptarGroup trading at $129.05 and data pointing to an estimated intrinsic value and analyst price target that are both higher, the key question is whether this gap signals a genuine opportunity or if the market already reflects potential future growth.

AptarGroup’s fair value in the most followed narrative sits at $161.43, comfortably above the recent $129.05 share price. This puts the focus squarely on whether the underlying growth and cash flow assumptions justify that gap.

The rapid expansion of AptarGroup’s proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Read the complete narrative.

Curious what kind of earnings path and margins need to hold up to support that valuation, and what future P/E multiple the narrative is banking on.

Result: Fair Value of $161.43 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this story can change quickly if ongoing legal expenses related to intellectual property or weaker demand for certain pharma and beauty systems place greater pressure on margins and cash flow.

Find out about the key risks to this AptarGroup narrative.

The earlier view leans on discounted cash flows to argue AptarGroup is trading below fair value. However, the current P/E of 21.2x is higher than both the peer average of 17.5x and the global packaging group on 15.7x, as well as a fair ratio of 18.6x. That richer multiple can mean less room for error if earnings or sentiment soften.

For a clearer sense of what this price gap might mean in practice, and whether the market could shift closer to that fair ratio over time, it helps to look at how the numbers stack up in detail, starting with See what the numbers say about this price — find out in our valuation breakdown.

Seeing both risks and rewards in the story so far is a good starting point, but the real edge comes from testing the details yourself with 4 key rewards and 1 important warning sign

If AptarGroup has caught your attention, do not stop here. Broaden your watchlist with a few focused stock ideas that could inform your next decision.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ATR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com